Zobrazeno 1 - 3 of 3 pro vyhledávání: '"Mitch Denker"'
1
Abstract CT250: A Phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors
Autor: Roel Funke, Mark W. Frohlich, Mihaela C. Cristea, Samuel Ejadi, Alex Franzusoff, Mehrdad Abedi, Bartosz Chmielowski, Mitch Denker, Todd Stallings-Schmitt
Publikováno v: Cancer Research. 80:CT250-CT250
Introduction: Neoepitopes (neoE) derived from private tumor-exclusive mutations represent compelling targets for personalized TCR-T cell therapy. An ultra-sensitive and high-throughput process was developed to capture tumor mutation-targeted CD8 T ce
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72df8cf58fd875fd4925f96339a6b42d
https://doi.org/10.1158/1538-7445.am2020-ct250
Zobrazit plný text záznamu
2
A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors
Autor: Todd Stallings-Schmitt, Mitch Denker, Mihaela C. Cristea, Bartosz Chmielowski, Mehrdad Abedi, Mark W. Frohlich, Samuel Ejadi, Alexis J. Franzusoff, Roel Funke
Publikováno v: Journal of Clinical Oncology. 38:TPS3151-TPS3151
TPS3151 Background: Neoepitopes (neoE) derived from private tumor-exclusive mutations represent compelling targets for personalized TCR-T cell therapy. An ultra-sensitive and high-throughput process was developed to capture tumor mutation-targeted CD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::945d9bff0820a034149cd6d6cb2ad968
https://doi.org/10.1200/jco.2020.38.15_suppl.tps3151
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje